Stay updated on Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial
Sign up to get notified when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.

Latest updates to the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedA new 'Locations' section has been added, including New Jersey and New York. The previous 'New Jersey Locations' and 'New York Locations' sections have been removed.SummaryDifference0.3%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedAdded note that publications are automatically filled from PubMed and may not be about the study, and updated the page revision to v3.3.2. The previous PubMed publication description and the old revision text were removed (v3.2.0).SummaryDifference0.1%

- Check46 days agoChange DetectedThe page no longer displays the government funding and operating-status notice that advised users about potential delays and directed them to cc.nih.gov and opm.gov for updates.SummaryDifference0.4%

- Check60 days agoChange DetectedThe study details, eligibility criteria, and interventions appear unchanged; only formatting and layout updates are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check88 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%

- Check95 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.